$27.3M
+$15.6M this year4 filings since 2025 · latest Equity filed
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing pioneering treatments for central nervous system diseases, focusing primarily on brain cancers such as glioblastoma. The company's innovative approaches seek to overcome the formidable challenge of delivering therapeutics across the blood-brain barrier, which has historically hindered effective treatment options.
What sets it apart
NeOnc's unique value lies in its proprietary nasal drug delivery system, which aims to enhance the effectiveness of treatments for brain cancers through a non-invasive administration method.
NEO100 is a highly purified form of perillyl alcohol (POH) that is administered intranasally. It is currently undergoing Phase II clinical trials specifically targeting patients with recurrent malignant glioma and malignant skull-based meningioma, aiming to provide an innovative solution in the treatment of these challenging CNS tumors.
